Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100694 | 1.00 | CES2 (0.35) | CES2CES1POLBGAAEPHX1 | |
| SCHEMBL2225284 | 1.00 | CES2 (0.35) | CES2CES1POLBGAAEPHX1 | |
| SCHEMBL1414056 | 0.98 | — | — | |
| SCHEMBL133774 | 0.98 | — | — | |
| SCHEMBL917888 | 0.90 | — | — | |
| SCHEMBL1118749 | 0.90 | — | — | |
| SCHEMBL5231305 | 0.90 | — | — | |
| SCHEMBL9020413 | 0.79 | EPHX1 (0.37) | CES2CES1EPHX1NPC1RAB9A | |
| SCHEMBL28707168 | 0.77 | EPHX1 (0.33) | CES2CES1POLBGAAEPHX1 | |
| SCHEMBL2224960 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0674528-A4 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM. | INSITE VISION INC (US) | 1996-06-26 | — | — | EP | claimed |
| EP-0682520-A1 | COMBINATION OF A CALCIUM CHANNEL BLOCKER AND AN ANTIOXYDANT FOR TREATING ISCHEMIC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | claimed |
| EP-0674528-A1 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994012217-A1 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1994-06-09 | — | — | WO | claimed |
| EP-0579754-A1 | USE OF AMINES TO SENSITIZE MULTIDRUG-RESISTANT CELLS | THE UPJOHN COMPANY (US) | 1994-01-26 | — | — | EP | claimed |
| EP-0293078-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1988-11-30 | — | — | EP | claimed |
| EP-2523959-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| EP-2523960-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-10-16 | — | — | EP | disclosed |
| EP-2523959-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523960-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086078-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086080-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| EP-0674528-A4 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM. | INSITE VISION INC (US) | 1996-06-26 | — | — | EP | disclosed |
| EP-0676953-A1 | PLASTICIZED BIOERODIBLE CONTROLLED DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1995-10-18 | — | — | EP | disclosed |
| EP-0674528-A1 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5436337-A | Anticarcinogenic agents | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| WO-1994014417-A1 | PLASTICIZED BIOERODIBLE CONTROLLED DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994014416-A1 | BIOERODIBLE CONTROLLED DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994012217-A1 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0579754-A1 | USE OF AMINES TO SENSITIZE MULTIDRUG-RESISTANT CELLS | THE UPJOHN COMPANY (US) | 1994-01-26 | — | — | EP | disclosed |